Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Aug 14, 2017	Evoke Pharma Reports Second Quarter 2017 Results and Highlights Collaborated with Spaulding Clinical Research LLC and today announced the initiation of the comparative exposure pharmacokinetic (PK) study Partnered with Rho, Inc. for the preparation of the 505(b)(2) New Drug Application (NDA) for Gimoti™ NDA submission remains on track for late 2017/early	View HTML Evoke Pharma Reports Second Quarter 2017 Results and Highlights 35 KB
Toggle Summary Aug 14, 2017	Evoke Pharma Initiates Comparative Exposure Pharmacokinetic Study for Gimoti™ Expected to be final clinical trial prior to 505(b)(2) NDA submission	View HTML Evoke Pharma Initiates Comparative Exposure Pharmacokinetic Study for Gimoti™ 35 KB
Toggle Summary Aug 07, 2017	Evoke Pharma Schedules Conference Call and Webcast for Second Quarter 2017 Financial Results SOLANA BEACH, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the Company will release financial results for the second quarter ended June 30, 2017 on Monday,	View HTML Evoke Pharma Schedules Conference Call and Webcast for Second Quarter 2017 Financial Results 14.6 KB
Toggle Summary May 31, 2017	Evoke Pharma Enters Agreement with Rho to Submit NDA for Gimoti Company on track for late 2017/early 2018 submission	View HTML Evoke Pharma Enters Agreement with Rho to Submit NDA for Gimoti 17.6 KB
Toggle Summary May 15, 2017	Evoke Pharma Reports First Quarter 2017 Results Confirmed FDA acceptability of comparative exposure pharmacokinetic (PK) study design and agreement on related CMC data package elements for Gimoti™ new drug application (NDA) Partnered with Spaulding Clinical Research to complete PK study in second half of 2017 Received FDA agreement that a	View HTML Evoke Pharma Reports First Quarter 2017 Results 32 KB
Toggle Summary May 10, 2017	Evoke Pharma Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at Digestive Disease Week 2017 Data Demonstrate Gimoti Significantly Improves Symptoms in Women with Moderate to Severe Diabetic Gastroparesis	View HTML Evoke Pharma Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at Digestive Disease Week 2017 22.3 KB
Toggle Summary May 01, 2017	Evoke Pharma Schedules Conference Call and Webcast for First Quarter 2017 Financial Results SOLANA BEACH, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the Company will release financial results for the first quarter ended March 31, 2017 on Monday, May	View HTML Evoke Pharma Schedules Conference Call and Webcast for First Quarter 2017 Financial Results 11.9 KB
Toggle Summary Apr 18, 2017	Evoke Pharma Announces Collaboration with Spaulding Clinical Research for the Gimoti Comparative Exposure Pharmacokinetic Trial SOLANA BEACH, Calif., April 18, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company has reached an agreement to work in partnership with Spaulding Clinical Research	View HTML Evoke Pharma Announces Collaboration with Spaulding Clinical Research for the Gimoti Comparative Exposure Pharmacokinetic Trial 15.7 KB
Toggle Summary Apr 04, 2017	Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharma's Proposed Comparative Exposure PK Trial for Gimoti NDA SOLANA BEACH, Calif., April 04, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company recently completed a positive Type A meeting with the U.S.	View HTML Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharma's Proposed Comparative Exposure PK Trial for Gimoti NDA 14.9 KB
Toggle Summary Mar 21, 2017	Evoke Pharma's Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017 SOLANA BEACH, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company's abstract detailing compelling Phase 3 trial data for Gimoti™	View HTML Evoke Pharma's Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017 15.8 KB